Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent molecular mechanisms underlie differential toxicity of trivalent lanthanum and divalent cadmium in Enchytraeus crypticus.

Ecotoxicology and environmental safety·2026
Same author

NF-κB p65 modulates the promoter activity of large yellow croaker (Larimichthys crocea) interleukin-2.

Developmental and comparative immunology·2026
Same author

Conformation-Adaptive Crown Ether-Polyimides as Superfast and Exceptionally Selective Artificial Na<sup>+</sup> Channels.

Angewandte Chemie (International ed. in English)·2026
Same author

High-Performance Artificial Lithium Channel Enabled by a Brominated Organic Imine Cage.

Angewandte Chemie (International ed. in English)·2026
Same author

Unanticipated Emergence of the Photo-Switchable Cs<sup>+</sup>-Selective Ion Channels From One-Dimensional 18-Crown-6 Arrays.

Angewandte Chemie (International ed. in English)·2026
Same author

Unraveling the Mechanism of Perillyl Alcohol and Its Derivatives as Potent Antifungal Agents against Gray Mold.

Journal of agricultural and food chemistry·2026

Related Experiment Video

Updated: Jul 16, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

A noncovalent approach to antiparallel beta-sheet formation.

Huaqiang Zeng1, Xiaowu Yang, Robert A Flowers

  • 1Department of Chemistry, Natural Sciences Complex, State University of New York, Buffalo, New York 14260, USA.

Journal of the American Chemical Society
|March 21, 2002
PubMed
Summary

Researchers created stable hybrid duplexes using peptide chains and a DNA template. These structures form beta-sheets, preventing aggregation and showing enhanced stability compared to individual components.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets
06:35

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Jul 16, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets
06:35

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Published on: March 29, 2024

Area of Science:

  • Supramolecular Chemistry
  • Biophysical Chemistry
  • Structural Biology

Background:

  • Peptide self-assembly is crucial for biological structures.
  • Designing stable peptide-DNA complexes remains a challenge.
  • Understanding molecular interactions guides the development of novel biomaterials.

Purpose of the Study:

  • To investigate the formation and stability of peptide-DNA hybrid duplexes.
  • To explore the structural consequences of attaching tripeptide chains to a DNA template.
  • To characterize the self-assembly behavior of peptides with and without a DNA scaffold.

Main Methods:

  • Synthesis of four tripeptide chains and a complementary DNA duplex.
  • Formation of hybrid duplexes by attaching peptides to DNA termini.
  • Structural characterization using 1D and 2D Nuclear Magnetic Resonance (NMR) spectroscopy.
  • Thermodynamic analysis via isothermal titration calorimetry (ITC).

Main Results:

  • Four distinct hybrid duplexes (1a.2a, 1a.2b, 1b.2a, 1b.2b) formed when peptides attached to the same DNA end, featuring two-stranded beta-sheet segments.
  • NMR confirmed extended peptide conformations, stabilized by hydrogen bonding and side-chain interactions.
  • The DNA template inhibited further peptide aggregation.
  • Attachment to different DNA termini resulted in undefined conformations, while peptides alone showed random association.
  • ITC revealed the hybrid duplex 1a.2a was thermodynamically more stable than the DNA template or peptides alone.

Conclusions:

  • Peptide chains can form stable, beta-sheet-rich hybrid duplexes with DNA templates.
  • The DNA duplex acts as a scaffold, directing peptide assembly and preventing aggregation.
  • Hybrid duplexes exhibit enhanced stability, offering potential for designing novel self-assembling systems.